Viktor Drvota

Viktor Drvota is a board member at OssDsign. Viktor has also served on the boards of Forendo Pharma Ltd, Aprea Therapeutics AB, Modus Therapeutics AB, and Promimic AB. Viktor is currently the chairman of the board of directors at Umecrine cognition AB.

Drvota has over 15 years of experience in the pharmaceutical industry. Viktor has expertise in ophthalmology, womens health, and cognition. Viktor has helped lead companies through successful exits, including the sale of Clanotech AB to Rosetta Capital and the sale of Forendo Pharma Ltd to Organon for 950 MUSD.

Viktor Drvota's educational career includes obtaining a Doctor of Medicine (M.D.) from the Karolinska Institutet, as well as a Doctor of Philosophy - PhD in Internal medicine from the same school. Viktor also completed an Interventional Cardiology Residency Program at the Karolinska Institutet. In addition, they hold a degree in Business and administration from the KTH Royal Institute of Technology. Viktor is currently an Associate professor in the field of Cardiology at the Karolinska Institutet.